Pfizer (United States)

Recent papers from Pfizer (United States)

1. Monitoring of adverse events following 2024–2025 BNT162b2 KP.2 COVID-19 vaccination in the United StatesVaccine · 2026
2. Incidence of medically attended Lyme borreliosis across endemic regions of six European countries (BOLD): a prospective multicentre active surveillance studyThe Lancet Regional Health - Europe · 2026
3. A Novel Measure of Association for Multivariate Data with ApplicationsAustrian Journal of Statistics · 2026
4. A Narrative Review of the Role of Adjuvants in Adult RSV VaccinesVaccines · 2026
5. FLAT-WHITE: from target trial emulation to federated high-throughput causal machine learning using decentralized real-world datanpj Health Systems · 2026
6. A robust meta-analytic approach for evaluating regional treatment effect in a multi-regional clinical trialJournal of Biopharmaceutical Statistics · 2026
7. A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of zavegepant for the acute treatment of migraine in Asian adultsThe Journal of Headache and Pain · 2026
8. Activity-based proteomics discovery of deubiquitinating enzyme inhibitors with immunomodulatory activitynpj Drug Discovery. · 2026
9. Real‐world diagnosis and treatment of individuals with migraine in the United States: The Migraine Insights in Diagnosis and Treatment ( MIND ) studyHeadache The Journal of Head and Face Pain · 2026
10. TCF21 loss identifies a conserved inflammation-associated fibroblast state across Crohn's disease and ulcerative colitis2026
11. Effectiveness of a bivalent RSV prefusion F protein-based vaccine in individuals with and without atherosclerotic cardiovascular disease: a prespecified analysis of the DAN-RSV trialEuropean Heart Journal · 2026
12. Quantitative Sciences in the Model‐Informed Era: From Parallel Functions to a Shared Decision SystemClinical Pharmacology & Therapeutics · 2026
13. Effect of bivalent RSV prefusion F protein-based vaccine on myocarditis and pericarditis: a prespecified safety analysis of the DAN-RSV trialEuropean Heart Journal · 2026
14. Estimated glomerular filtration rate trajectories by transthyretin stabilisation status in ATTR-ACTEuropean Heart Journal · 2026
15. Diagnosis of transthyretin amyloid cardiomyopathy using automated myocardial segmentation and CT-based radiomic phenotypingEuropean Heart Journal · 2026
16. Effectiveness of bivalent RSV prefusion F protein-based vaccine in individuals with and without atrial fibrillation: a prespecified analysis of the DAN-RSV trialEuropean Heart Journal · 2026
17. The effect of quality of life on all cause mortality in tafamidis treated vs. placebo ATTR-CM patients: post hoc analyses from the ATTR-ACT studyEuropean Heart Journal · 2026
18. Building on the demonstrated functional benefit of tafamidis: association of TTR stabilisation with 6MWT outcomes in ATTR ACTEuropean Heart Journal · 2026
19. Effectiveness of RSV vaccine against cardio-respiratory hospitalizations in heart failure: a prespecified analysis of the DAN-RSV trialEuropean Heart Journal · 2026
20. Long-term Sequelae in Children With Invasive Meningococcal Disease, Chile 2009–2023The Pediatric Infectious Disease Journal · 2026